

Zydelig® – Prior Authorization Request (For Maryland Only)

Send completed form to: Case Review Unit CVS/caremark Specialty Programs Fax: 866-249-6155

CVS/caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS/caremark toll-free at 866-249-6155.** If you have questions regarding the prior authorization, please contact CVS/caremark at **866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 800-237-2767.

Patient Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

1. What drug is being prescribed? Zydelig® Other _____
2. What is the patient's diagnosis?
 Chronic lymphocytic leukemia (CLL) Follicular B-cell non-Hodgkin lymphoma (FL)
 Small lymphocytic lymphoma (SLL) Other _____
3. What is the ICD code? _____
4. Would the prescriber like to request an override of the step therapy requirement? Yes No If no, skip to #7.
5. Has the member received the medication through a pharmacy or medical benefit within the past 180 days? Yes No
ACTION REQUIRED: Please provide documentation to substantiate the member had a prescription paid for within the past 180 days (i.e., PBM medication history, pharmacy receipt, EOB etc.)
6. Is the medication effective in treating the member's condition? Yes No
 Continue to #7 and complete this form in its entirety.
7. Is the disease relapsed or refractory? Yes No
8. Does the patient have history of serious allergic reactions including anaphylaxis or toxic epidermal necrolysis?
 Yes No

Complete the following section based on the patient's diagnosis

Section A: Chronic Lymphocytic Leukemia (CLL)

9. Will Zydelig® be used in combination with rituximab [Rituxan®]? Yes No

Section B: Follicular B-cell Non-Hodgkin Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL)

10. Has the patient received at least TWO prior systemic therapies? Yes No

Document prior therapies: _____

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS/caremark or the benefit plan sponsor.

X _____
Prescriber or Authorized Signature **Date: (mm/dd/yy)**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Zydelig SGM 8/2014

CUT9689-1E - For Maryland Only